MedTrace Logo

Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas

NCT02388659 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 142

Last updated 2023-01-31

No results posted yet for this study

Summary

The Investigators will examine the disease specificity of 2-hydroxyglutarate in non-glioma brain lesions, and the clinical utility of 2-hydroxyglutarate, glycine and citrate in IDH mutated gliomas and IDH wild type gliomas.

Conditions

  • Malignant Gliomas
  • Oligodendrogliomas
  • Astrocytomas

Interventions

DEVICE

3 Tesla scanning

Approximately 38 brain tumor patients with IDH mutated gliomas and 50 patients with non-glioma disease will be scanned.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Changho Choi, PhD · UT Southwestern Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02388659 on ClinicalTrials.gov